Article
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Oncotarget - 22 Mar 2016
Takahashi Koichi, Patel Keyur, Bueso-Ramos Carlos, Zhang Jianhua, Gumbs Curtis, Jabbour Elias, Kadia Tapan, Andreff Michael, Konopleva Marina, DiNardo Courtney, Daver Naval, Cortes Jorge, Estrov Zeev, Futreal Andrew, Kantarjian Hagop, Garcia-Manero Guillermo
Abstract excerpt
We screened TP53 mutations in 168 MDS patients who were treated with HMA and evaluated predictive and prognostic value of TP53 mutations. Overall response to HMA was not different based on TP53 mutation status (45% vs. 32% in TP53-mutated and wild type [WT], respectively, P = 0.13). However, response duration was significantly shorter in TP53-mutated patients compared to WT patients (5.7 months vs. 28.5 months, P...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.